Federal Court Reaffirms Jurisdiction of the Patented Medicines Prices Review Board
The Federal Court of Appeal took the occasion of an appeal of the order of the Patented Medicines Prices Review Board (the “Board”) that required a patentee to share reports on medicines that were no longer under patent, to reaffirm the jurisdiction of the Board.
Courts have consistently held that the Board’s jurisdiction is limited to patented medicines and does not extend to medicines for which the patent has expired.[1]
The Board ordered Galderma Canada Inc. (“Galderma”) to provide reports on sales for six years after the patent had expired.
Galderma had provided the reports while the medicine was . . . [more]